RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.